medRxiv
December 12, 2019
Ron Shore, Paul Ioudovski, Craig Goldie et al.
8 citations
preprint
Abstract We conducted a scoping review on psilocybin-assisted therapy for addiction, depression, anxiety and post-traumatic stress disorder. Psilocybin is a naturally-occurring tryptophan derivative found in species of mushroom with psycho-active properties. From 2022 records identified by database searching, 40 publications were included in the qualitative synthesis from which we identified 9...
Journal of Psychedelic Studies
December 5, 2019
Belinda Eriacho
Although Native American communities are unique in their beliefs, traditions, and languages, there are some fundamental common belief systems shared by most Native American cultures. Therapists and other practitioners engaging in a healing relationship with Native Peoples should be aware of these fundamental aspects of the Native American culture. This includes trust/respect, confidentiality...
Psychopharmacology
November 29, 2019
Sam G. Moreton, Luke Szalla, Rachel E. Menzies et al.
77 citations
Psychedelic therapies can engender enduring improvements in psychological well-being. However, relatively little is known about the psychological mechanisms through which the salutary effects of psychedelics emerge. Through integrating extant research on psychedelics with contemporary existential psychology, we present a novel hypothesis that reduced death anxiety may be a key mechanism...
International Journal of Drug Policy
November 25, 2019
Toby Lea, Nicole Amada, Henrik Jungaberle et al.
119 citations
BackgroundIn recent years there has been growing media attention on microdosing psychedelics (e.g., LSD, psilocybin). This refers to people routinely taking small doses of psychedelic substances to improve mental health and wellbeing, or to enhance cognitive performance. Research evidence is currently limited. This paper examines microdosing motivations, dosing practices, perceived short-term...
Australian & New Zealand Journal of Psychiatry
November 22, 2019
Sally Meikle, Paul Liknaitzky, Susan L. Rossell et al.
19 citations
In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use in the clinical environment,...
Neuropsychopharmacology
November 16, 2019
Friederike Holze, Patrick Vizeli, Felix Müller et al.
250 citations
Abstract Lysergic acid diethylamide (LSD) is a classic psychedelic, 3,4-methylenedioxymethamphetamine (MDMA) is an empathogen, and d -amphetamine is a classic stimulant. All three substances are used recreationally. LSD and MDMA are being investigated as medications to assist psychotherapy, and d -amphetamine is used for the treatment of attention-deficit/hyperactivity disorder. All three...
Journal of Affective Disorders
November 1, 2019
Silvia Muttoni, Maddalena Ardissino, Christopher John
265 citations
Depression and anxiety are prevalent psychiatric disorders that carry significant morbidity. Pharmacological and psychosocial interventions are used to manage these conditions, but their efficacy is limited. Recent interest into the use of psychedelic-assisted therapy using ayahuasca, psilocybin or lysergic acid diethylamide (LSD) may be a promising alternative for patients unresponsive to...
Journal of Psychedelic Studies
September 19, 2019
Logan Neitzke-Spruill
58 citations
Background and aims Set and setting function both as a concept that guides research and practice with psychedelic drugs and as a meme aimed at reducing harm among psychedelic users. Referring to non-pharmacological factors that shape drug experiences, the concept of set and setting was popularized in the West during the mid-20th century. However, little theoretical development has occurred...
Drug and Alcohol Review
September 5, 2019
Elena Argento, Rielle Capler, Gerald Thomas et al.
98 citations
Abstract Introduction and Aims A previous observational study of ayahuasca‐assisted therapy demonstrated statistically significant reductions in self‐reported problematic cocaine use among members of an Indigenous community in Canada. This paper aims to qualitatively explore the impact of ayahuasca‐assisted therapy on addiction and other substance use‐related outcomes and elucidate the lived...
Journal of Psychedelic Studies
July 30, 2019
Tehseen Noorani
112 citations
This commentary considers efforts to turn psychedelics into medications that can be administered through healthcare systems as examples of “medicalization.” I draw on ethnographic research both inside and outside of university-based clinical trials from 2014 to date, together with analogous examples from psychiatry and drug research and development. Rather than taking a normative stance on...